Dec 2022: Completion of short invivo trial at Mount Sinai of the device. 

June 2022: Completed updated design of the SEAL device with our partners from Mount Sinai Medical Center, Bioengineering Department. 

May 2020: KidneyX Redesign Dialysis Phase 2 Honorable Mention

Aug 2019: Presented at the IDEAS conference in Seattle,  https://cdi.washington.edu/ideas/ on Innovation in Dialysis.

April 2019: Winner in the KidneyX Redesign Dialysis prize competition Phase 1

April 2019: 3rd Innovation & Entrepreneurship International Competition, Shenzhen, China. Third Prize, Biology and Life Technology Final

​

Mar 2018: Selected participant at the 1st China (Ningbo) Global Experts Summit (CGES) http://www.ocstab.net/index.php/en/activities-news/activity-details/the1st-china-ningbo-global-experts-summit-cges

​

Nov. 2017: Selected participant in the Global Startup Program Asia + in Taipei, Taiwan.  http://www.garageplus.asia/en/startups

Mission Statement: "We believe that entrepreneurs are mission-driven individuals who take actions to realize their dreams and bring a better life to society through innovation."

​

May 2017: Mixiii Biomed 2017 conference, table in the Start-Up Pavilion.

​

April 2017: Successful completion of 9-month vascularized tissue in-growth tissue study in rodents.  Study reports by an expert histopathologist, Dr. Abraham Nyska, DVM, Dipl. ECVP, Fellow IATP. Slides prepared by Alizee Pathology, Thurmont, MD. 

​

Nov 2016: Access for Life a Silver Award Winner of MassChallenge 2016.

Watch: https://www.youtube.com/watch?v=C9_fo75JnXk 

​

July 2016: Next stage of animal trials commenced at the GLPigs CRO, Assaf Harofeh Medical Center, Rishon Lezion, Israel.

​

May 2016: Won a place in the MassChallenge Accelerator Program in Jerusalem.

​

April  2016: Won a EU Horizon 2020 Phase 1 SME Grant. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 728915.

​

Jan. 2016:  Pharmes Innovations Limited investment received, which will be used to fund the animal trials. As a result, David Grey has joined the Board of Directors.

 

Dec. 2015: Initial round of the large animal trials, pilot stage,  completed at the GLPigs CRO at Assaf Harofeh Medical Center, Tzrifin, Israel.

 

May 2015: Our CEO, Philip Libman, presented at the Israel Advanced Technology Institute’s Biomed 2015 Conference in Tel Aviv. 

​

Picture from Biomed 2017 conference. From left: Dr. Yehuda Zicherman, Eyal Teichman, Philip Libman